Truist analyst Terry Tillman raised the firm’s price target on UiPath to $28 from $20 and keeps a Buy rating on the shares. The company’s Q3 results were “very strong” with upside in revenue, ARR and profitability, the analyst tells investors in a research note. UiPath is an automation leader and should benefit from notable GenAI interest owing to its differentiated approach of combining GenAI with Specialized AI, the firm adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PATH: